SWK (NASDAQ:SWKH) Shares Up 0.4% – What’s Next?

SWK Holdings Co. (NASDAQ:SWKH)’s stock price was up 0.4% during trading on Wednesday . The company traded as high as $16.25 and last traded at $15.85. Approximately 3,815 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 10,682 shares. The stock had previously closed at $15.79.

SWK Price Performance

The stock has a market capitalization of $192.74 million, a P/E ratio of 17.04 and a beta of 0.36. The company’s 50 day simple moving average is $16.60 and its two-hundred day simple moving average is $16.93. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.06 and a quick ratio of 5.06.

Institutional Investors Weigh In On SWK

Large investors have recently bought and sold shares of the business. Barclays PLC increased its holdings in shares of SWK by 185.0% in the third quarter. Barclays PLC now owns 4,461 shares of the company’s stock valued at $77,000 after purchasing an additional 2,896 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of SWK in the 2nd quarter worth $172,000. Dimensional Fund Advisors LP increased its holdings in SWK by 85.7% in the second quarter. Dimensional Fund Advisors LP now owns 30,109 shares of the company’s stock valued at $511,000 after purchasing an additional 13,892 shares during the last quarter. SkyView Investment Advisors LLC lifted its stake in SWK by 7.7% in the second quarter. SkyView Investment Advisors LLC now owns 31,165 shares of the company’s stock valued at $529,000 after buying an additional 2,234 shares during the period. Finally, Victory Capital Management Inc. bought a new position in SWK during the third quarter worth about $589,000. 99.27% of the stock is currently owned by institutional investors.

SWK Company Profile

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.